Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cellectis S.A.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with relapsed or primary refractory AML (as defined in World Health Organization \[WHO\] criteria) with ≥5% bone marrow blasts
Patients with CD123+ blast cells (verified by flow cytometry)
Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of ≤1
Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within screening period
(Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion (LD)
Other criteria may apply
You may not be if
Patients with acute promyelocytic leukemia (APL) or central nervous system (CNS) Leukemia
Previous investigation gene or cell therapy (including CAR)
